IN THE CLAIMS:

Please amend claims as follows.

1. (currently amended) Biodegradable colloidal particles comprising

~~a) amphiphilic comb polymers comprising a water-soluble polyol backbone, hydrophobic side chains and primary, secondary, tertiary or quaternary side chains carrying amino groups and~~

~~b) as a stabilizer, at least one negatively charged organic base, which can be a Lewis or Brønsted base, or the corresponding acid thereof, which can be a Lewis or Brønsted acid~~

~~wherein~~

~~the acid groups of the stabilizer are available in excess or deficiency in relation to the primary, secondary, or tertiary amino groups of the comb polymers, or~~

~~the basic groups are available in deficiency or excess in relation to the quaternary amino groups of the comb polymers,~~

~~so that the colloidal particles feature a positive or negative zeta potential.~~



~~wherein n+3, P is the polyol backbone, and R', R'' is C2-Alkyl and R^4, R^2 is H,~~

~~the water-soluble polyol backbone is polyvinyl alcohol (PVAL),~~

~~the hydrophobic side chains are poly (lactide-co-glycides), and~~

~~the stabilizer is a combination of CMC and one or more pharmaceutically active substances~~

a) amphiphilic comb polymers comprising a water-soluble polyol backbone, hydrophobic side chains and side chains carrying amino groups consisting of the formula



b) as a stabilizer, at least one negatively charged organic base, which can be a Lewis or Brønsted base, or the corresponding acid thereof, which can be a Lewis or Brønsted acid,

wherein

the acid groups of the stabilizer are available in excess or deficiency in relation to the amino groups of the comb polymer,

so that the colloidal particles feature a positive or negative zeta potential,

wherein the stabilizer is a combination of CMC and one or more pharmaceutically active species.

2. canceled

3. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the pharmaceutically active substance is a carboxylic acid, sulphonic acid or phosphoric acid.

4. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the active substance is a prostanoid.

5. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the pharmaceutically active substance is Iloprost®.

6-8. canceled

9. (previously presented) Biodegradable colloidal particles according to claim 1, wherein 0.5 to 50 % of the hydroxy groups of the polyol backbone of the comb polymer possess linked side chains carrying amino groups and 1 to 90% of the hydroxy groups of the polyol backbone possess linked hydrophobic side chains.

10. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the amino groups of the comb polymer are at least partly quaternary amino groups, which were quaternized via the addition of an organic acid and stabilized via the corresponding negatively charged organic base which resulted from this.

11. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the zeta potential lies between -5 and -80 mV or between +5 and +80 mV.

12. (previously presented) Biodegradable colloidal particles according to claim 1, wherein the organic acid is a prostanoid and the zeta potential lies between -10 and -50 mV or between +10 and +50 mV.

13. (previously presented) A method of use of biodegradable colloidal particles according to claim 1 for the application of an acidic or basic pharmaceutically active substance for the treatment of diseases in humans and mammals.

14. (previously presented) A method of use of biodegradable colloidal particles according to claim 1 for the inhalative (pulmonary) application of an acidic or basic active substance.

15. (previously presented) A method of use of biodegradable colloidal particles according to claim 1, wherein the pharmaceutically active substance is a prostanoid.

16. (previously presented) A method of use of biodegradable colloidal particles according to claim 1 for the treatment of pulmonary hypertension.

17. (previously presented) A method of use according to claim 1, wherein the biodegradable colloidal particles are available in a physiologically compatible aqueous solution.

18. (previously presented) Method for the production of biodegradable colloidal particles according to claim 1 encompassing the following steps for production,

a) dissolution of a comb polymer comprising a water-soluble polyol backbone, hydrophobic side chains and side chains carrying primary, secondary, tertiary or quaternary amino groups in a water-miscible, volatile organic solvent and

b) addition of the solution obtained in a) to an isotonic aqueous solution with a pH value between 6.0 and 8.0 comprising, along with a sugar and a buffer, an

organic acid, which can be a Lewis or Brønsted acid, or the corresponding base thereof, which can be a Lewis or Brønsted base,

c) stirring of the solution obtained in (b) for the production of colloidal particles and

d) removal of the organic solvent.

19-24. canceled